Introduction {#s1}
============

Digestive tract cancers, especially gastric, esophageal and colorectal cancers, are a major global health problem. Globocan data in 2008 showed [@pone.0096301-Ferlay1] that the standardized incidence of colorectal cancer, gastric cancer and esophageal cancer were located in 4th, 6th and 9th in all tumors, respectively. The standardized mortality rate of gastric cancer, coming after lung cancer and breast cancer, ranked the third place. Moreover, colorectal cancer and esophageal cancer also ranked top ten in cancer mortality rankings. The incidence of different cancer varies widely among different racial and ethnic groups which may be partly attributed to lifestyle and genetic background [@pone.0096301-Iscovich1]. Exposure to environmental carcinogens can cause different types of DNA damage that subsequently lead to carcinogenesis of different tissues, if left unrepaired [@pone.0096301-Zhu1].

DNA repair mechanisms, such as the nucleotide excision repair (NER), base excision repair pathway (BER) and double-strand break pathway, are essential for maintaining genome integrity and preventing carcinogenesis. NER, the most versatile, well studied DNA repair mechanism in humans, is mainly responsible for repairing bulky DNA damage, such as DNA adducts caused by UV radiation, mutagenic chemicals, or chemotherapeutic drugs [@pone.0096301-Shi1]. The major component of NER, xeroderma pigmentosum group D (*XPD* or *ERCC2*), mapped in chromosome 19q13.3, spans over 20 kb, contains 23exons and encodes the 761-amino acid protein. It has two functions: nucleotide excision repair and basal transcription as part of the transcription factor complex (TFIIH) [@pone.0096301-Spitz1]. Mutations on different sites in *XPD* gene can give rise to repair and transcription defects, and altered DNA repair capacity can render a higher risk of developing different types of cancer [@pone.0096301-Spitz1]--[@pone.0096301-Hemminki1]. Several polymorphisms of *XPD* were identified, like Asp312Asn, Lys751Gln, Arg194Trp and Arg399Gln. The XPD polymorphic loci that has been of particular interest in molecular epidemiology studies is the Lys751Gln polymorphism (rs13181) in exon 23 [@pone.0096301-Shen2]. The lysine to glutamine transition at position 751 in exon 23 may affect different protein interactions, diminish the activity of TFIIH complexes, and alter the genetic susceptibility to cancer [@pone.0096301-Shen3].

Genetic variant in *XPD* Lys751Gln had been demonstrated to be associated with some cancers risk in different meta-analysis, such as esophageal cancer, gastric cancer, colorectal cancer, breast cancer, prostate cancer, lung cancer and bladder cancer [@pone.0096301-Xue1]--[@pone.0096301-Wang1]. However, due to an insufficient number of publications, they did not calculate pooled odds ratios (ORs) of digestive tract cancers comprehensively. In consideration of the extensive role of *XPD* in digestive tract cancers, we performed a meta-analysis of all 37 eligible case--control studies: oral cancer, esophageal cancer, gastric cancer <http://www.sciencedirect.com/science/article/pii/S0188440911000853> - bib10and colorectal cancer, to derive a more precise association of *XPD* Lys751Gln polymorphism and different types of digestive tract cancers risk.

Materials and Methods {#s2}
=====================

Identification of eligible studies {#s2a}
----------------------------------

Using PubMed, we identified all published case--control studies which investigated the association between the *XPD* Lys751Gln polymorphism and digestive tract cancers risk using a retrieving query formulation "(*XPD* or ERCC2) polymorphisms AND (colorectal cancer OR gastric cancer OR esophageal cancer OR oral cancer)".The digestive tract cancers in this article refer to oral cancer, esophageal cancer, gastric cancer and colorectal cancer. We also searched references in published articles and reviews on this topic in PubMed. Eligible studies had to meet the following criteria: (a) only case-control designs were considered, (b) The study explored the correlation between different types of digestive tract cancers and *XPD* Lys751Gln polymorphism. Major exclusion criteria were (a) no control population, (b) no available genotype frequency. (c) Genotypic distribution of the controls was not in agreement with Hardy-Weinberg equilibrium (HWE). (d) Duplication of the previous publications, the largest or most recent publication was selected.

Data Extraction {#s2b}
---------------

Information was carefully extracted from all eligible publications independently by two authors according to the inclusion criteria listed above. If the two pieces of typed data were different, a third investigator would be asked to check and to make sure all data were right. The following information was extracted from each study: first author, year of publication, country of study population, ethnicity, source of controls, number of cases and controls with different genotypes and HWE ([Table 1](#pone-0096301-t001){ref-type="table"}).
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###### Characteristics of XPD polymorphisms Included in the Meta-analysis.

![](pone.0096301.t001){#pone-0096301-t001-1}

  study                                    Year   Ethnicity   Source of controls   Cases   Controls   *P* for HWE                                 
  --------------------------------------- ------ ----------- -------------------- ------- ---------- ------------- ----- ------ ----- ----- ----- ------
  **Oral cancer**                                                                                                                                 
  Surya                                    2005     Asian             PB            110       49          46        15    110    71    31     8    0.09
  Da-Tian                                  2007     Asian             HB            154      134          18         2    105    89    15     1    0.68
  Mousumi                                  2007     Asian             HB            388      190          158       40    309    158   125   26    0.85
  Suparp                                   2005     Asian             PB            105       83          21         1    164    126   36     2    0.74
  **Esophageal cancer**                                                                                                                           
  Xing                                     2002     Asian             HB            433      367          63         3    524    451   70     3    0.87
  Xing                                     2003     Asian             HB            325      278          44         3    383    331   49     3    0.43
  Yu                                       2004     Asian             HB            135      108          16        11    152    133   17     2    0.10
  Alan                                     2005   European            HB            56        31          21         4     95    34    46    15    0.93
  Ye                                       2006   European            PB            303       99          156       48    472    198   203   71    0.11
  Geoffrey                                 2007   European            HB            182       61          98        23    336    143   161   32    0.16
  Ranbir                                   2007     Asian             HB            120       52          61         7    160    63    77    20    0.63
  Darren                                   2008   European            HB            312      104          159       49    453    193   208   52    0.72
  Heather                                  2008   European            PB            208       80          94        34    247    91    121   35    0.60
  James                                    2008   European            PB            263      108          123       32    1337   575   588   174   0.22
  Jennifer                                 2009   European            HB            346      137          153       56    456    187   216   53    0.43
  Zhai                                     2009     Asian             HB            200      167          31         2    200    148   51     1    0.12
  Huang                                    2012     Asian             HB            213      150          55         8    358    274   79     5    0.79
  **Gastric cancer**                                                                                                                              
  Huang[a](#nt103){ref-type="table-fn"}    2005   European            PB            279      381          107       126    46    145   163   73    0.03
  Lou                                      2006    Asians             HB            238      205          30         3    200    164   33     3    0.38
  Ye                                       2006   European            PB            126       49          61        16    472    198   203   71    0.11
  Ruzzo                                    2007   European            PB            89        29          44        16     94    25    53    16    0.18
  Zhou                                     2006    Asians             PB            253      224          26         3    612    522   86     4    0.82
  Gabriel                                  2008   European            HB            245       99          105       41    1172   447   555   170   0.91
  Doecke                                   2008   European            PB            303      127          140       36    1337   575   588   174   0.22
  Zhang                                    2009    Asians             PB            207      166          39         2    212    172   39     1    0.43
  Domenico                                 2010   European            PB            295       90          157       48    546    177   284   85    0.09
  EMEL                                     2010   European            PB            40        14          18         8    247    102   114   31    0.92
  Long[a](#nt103){ref-type="table-fn"}     2010    Asians             HB            361      616          139       151    71    400   164   52    0.00
  Ayse[a](#nt103){ref-type="table-fn"}     2011   European            HB            106      116          30        56     20    40    43    33    0.01
  **Colorectal cancer**                                                                                                                           
  Camilla                                  2006    Asians             PB            105       43          47        15    331    148   142   41    0.44
  Mariana                                  2006   European            PB            740      387          298       55    789    392   317   80    0.18
  Skjelbred                                2006   European            PB            156       58          76        22    398    175   173   50    0.48
  Victor                                   2006   European            HB            357      158          150       49    318    135   145   38    0.92
  Mariana                                  2007    Asians             PB            303      251          48         4    1163   998   159    6    0.90
  Chih-Ching                               2007    Asians             HB            717      602          112        3    731    631   96     4    0.86
  Rikke                                    2007   European            PB            396      160          178       58    798    311   382   105   0.47
  Tomasz                                   2009   European            HB            100       56          33        11    100    42    41    17    0.21
  Wang                                     2010    Asians             HB            302      138          130       34    291    137   117   37    0.13
  Jelonek                                  2010   European            PB            123       54          47        22    153    66    68    19    0.81
  Canbay                                   2011   European            PB            79        31          37        11    247    102   114   31    0.92

HB: hospital based.

PB: population based.

: Hardy--Weinberg Equilibrium (HWE) in controls: *P*\<0.05. Overall analysis and subgroup analysis does not include these studies\' data.

Statistical Analysis {#s2c}
--------------------

We assessed the departure from the Hardy--Weinberg equilibrium for the control group in each study using Pearson\'s goodness-of-fit χ^2^test with 1 degree of freedom. Heterogeneity among studies was checked by the random-effects model (the Der Simonian and Laird method) if there was significant heterogeneity [@pone.0096301-DerSimonian1]. A *P* value of more than the nominal level of 0.05 for the Q statistic indicated a lack of heterogeneity across studies, allowing for the use of the fixed -effects model (the Mantel--Haenszel method) [@pone.0096301-Mantel1]. If *P* value less than 0.05 was considered as having heterogeneity, the results can not be pooled together and discussed. The risks ORs of digestive tract cancers associated with the *XPD* Lys751Gln polymorphism were estimated for each study. The pooled ORs were evaluated on co-dominant model (Lys/Gln *vs*.Lys/Lys, Gln/Gln *vs*. Lys/Lys), dominant model (Gln/Gln + Lys/Gln *vs*. Lys/Lys), recessive model (Gln/Gln *vs*. Lys/Gln+Lys/Lys), respectively. Subgroup analyses were performed by cancer types, ethnicity and source of controls. The publication bias was diagnosed by the funnel plot, in which the standard error of log (OR) of each study was plotted against its log (OR). Funnel plot asymmetry was assessed by Egger\'s linear regression test. The significance of the intercept was determined by the t test suggested by Egger (*P*\<0.05 was considered representative of statistically significant publication bias) [@pone.0096301-Egger1]. All the statistical tests were performed with STATA version11.0 (Stata Corporation, College Station, TX, USA).

Results {#s3}
=======

Study characteristic {#s3a}
--------------------

A total of 107 potential relevant studies were retrieved through PubMed ([Figure 1](#pone-0096301-g001){ref-type="fig"}). After carefully reviewing, 40 eligible case-control studies (3 studies not consistent with HWE were also shown) on the relationship between *XPD* Lys715Gln polymorphism and digestive cancers risk were involved in this meta-analysis, including 4 oral cancer studies [@pone.0096301-Bau1]--[@pone.0096301-Kietthubthew1], 13 esophageal cancer studies [@pone.0096301-Huang1]--[@pone.0096301-Xing4], 12 gastric cancer studies [@pone.0096301-Doecke1], [@pone.0096301-Lou1]--[@pone.0096301-Huang2] and 11 colorectal cancer studies [@pone.0096301-Canbay2]--[@pone.0096301-Skjelbred2]. As shown in [Table 1](#pone-0096301-t001){ref-type="table"}, 17 studies were conducted in Asians, 20 studies in Europeans. In addition, there were 18 hospital-based studies, 19 population-based studies. Diverse genotyping methods were used, including PCR-RFLP, PCR-SSCP, Taqman, Real-time PCR and SEB PCR. All studies indicated that the genotypic distribution of the controls were consistent with HWE.

![Flow diagram of studies identification.](pone.0096301.g001){#pone-0096301-g001}

Meta-analysis {#s3b}
-------------

Table2 lists the main results of the meta-analysis for *XPD* Lys751Gln: having the Gln/Gln genotype is a risk factor for digestive tract cancers: GlnGln *vs*. LysLys: OR = 1.12, 95% CI = 1.01--1.24, *P* = 0.029, *P* ~heterogeneity~ = 0.133. *I* ^2^ = 20.9% ([Figure 2](#pone-0096301-g002){ref-type="fig"}). We did not find any significant association between the other genetic models and digestive tract cancers. The results of stratified analysis by cancer type, source of controls and ethnicity were shown in [table 2](#pone-0096301-t002){ref-type="table"}. The Gln/Gln vs. Lys/Lys genotype had an elevated risk in Asian population (OR = 1.28, 95% CI = 1.01--1.63, *P* = 0.045, *P* ~heterogeneity~ = 0.287, *I* ^2^ = 14.2%; [Figure 3](#pone-0096301-g003){ref-type="fig"}). High heterogeneity was found in esophageal cancer and hospital-based studies, so the results can not be pooled together. In addition, the results did not suggest any association between *XPD* Lys751Gln polymorphism and digestive cancers susceptibility for all genetic models in European individuals or in population-based studies overall.

![Forest plot of digestive cancer risk associated with the XPD Lys751Gln polymorphisms.\
Homozygote comparison.](pone.0096301.g002){#pone-0096301-g002}

![Forest plot of digestive cancer risk associated with the XPD Lys751Gln polymorphisms in Asian subgroups (based on homozygote comparison).\
A fixed-effects model was used. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](pone.0096301.g003){#pone-0096301-g003}
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###### Pooled ORs and 95%CIs of stratified meta-analysis.

![](pone.0096301.t002){#pone-0096301-t002-2}

  Stratification       No.case/control                 GlnGln *vs*.LysLys                  GlnLys *vs*.LysLys              GlnGln+GlnLys *vs*.LysLys              GlnGln *vs*.GlnLys+LysLys                                                                               
  ------------------- ----------------- ------------------------------------------------- -------------------- ------------------------------------------------- --------------------------- -------------------------------------------------- ------- ----------------- -------
  Total                40(9773/17185)                    1.12(1.01,1.24)                         0.029                         1.04(0.98--1.11)                             0.194             1.06(1.00,1.12)[b](#nt105){ref-type="table-fn"}    0.064   1.09(0.99,1.20)   0.072
  Cancer type                                                                                                                                                                                                                                                             
  Colorectal cancer     11(3378/5319)                    0.99(0.3,1.17)                          0.870                          0.99(0.89,1.09)                             0.776                             0.99(0.90,1.09)                    0.790   1.00(0.85,1.17)   0.954
  Gastric cancer        12(2542/5905)                    1.05(0.85,1.29)                         0.639                          0.97(0.85,1.10)                             0.612                             0.98(0.86,1.11)                    0.744   1.05(0.87,1.28)   0.630
  Esophageal cancer     13(3096/5173)    1.29(1.08,1.54)[b](#nt105){ref-type="table-fn"}         0.005          0.90(0.81,1.00)[b](#nt105){ref-type="table-fn"}             0.056             0.91(0.77,1.07)[b](#nt105){ref-type="table-fn"}    0.235   0.84(0.66,1.07)   0.159
  Oral cancer            4(757/688)                      1.50(0.96,2.35)                         0.078                          0.88(0.60,1.30)                             0.518                             0.85(0.56,1.28)                    0.430   0.72(0.47,1.12)   0.147
  Ethnicity                                                                                                                                                                                                                                                               
  Asian                 18(4669/6521)                    1.28(1.01,1.63)                         0.045                          1.05(0.95,1.17)                             0.340                             1.08(0.98,1.19)                    0.133   1.21(0.96,1.53)   0.110
  European             22(5104/10564)                    1.09(0.97,1.22)                         0.144                          1.04(0.96,1.12)                             0.363                             1.05(0.97,1.13)                    0.232   1.07(0.96,1.19)   0.210
  Source of control                                                                                                                                                                                                                                                       
  HB                    20(5290/7075)    1.19(1.01,1.40)[b](#nt105){ref-type="table-fn"}         0.038                          1.02(0.93,1.12)                             0.703             1.02(0.89, 1.16)[b](#nt105){ref-type="table-fn"}   0.787   1.16(0.95,1.41)   0.140
  PB                   20(4483/10010)                    1.08(0.94,1.23)                         0.267                          1.06(0.98,1.16)                             0.157                             1.07(0.98,1.15)                    0.122   1.04(0.92,1.18)   0.715

NO: involved studies\' number; *Gln Lys VS*.LysLys: Heterozygote comparison; GlnGln *vs*.LysLys: Homozygote comparison; GlnGln+GlnLys *vs*. LysLys: Dominant model; GlnGln *vs*. GlnLys+LysLys: Recessive model; Random model was chosen for data pooling when *P*\<0.10 and/or *I^2^*\>50%; otherwise fixed model was used.

the results were excluded due to potential heterogeneity.

Sensitivity analysis {#s3c}
--------------------

In the sensitivity analysis, when each particular study had been removed meta-analyses were conducted repeatedly. The corresponding pooled ORs were not qualitatively altered with or without this study. As shown in [Figure 4](#pone-0096301-g004){ref-type="fig"}, the most influencing single study on the overall pooled OR estimates seemed to be the one conducted by Mariana et al, which had a relatively large sample size. However, after the removal of the study, the result of the meta-analysis did not been influenced significantly: Gln/Gln vs. Lys/Lys: OR = 1.17, 95% CI: 1.05--1.30, indicating high stability of our results.

![Influence analysis of the summary odds ratio coefficients on the association between XPD Lys751Gln homozygote comparison with digestive tract cancers risk.\
Results were computed by omitting each study (left column) in turn. Bars, 95% CI.](pone.0096301.g004){#pone-0096301-g004}

Heterogeneity analysis {#s3d}
----------------------

There was moderate heterogeneity among these studies in GlnGln+GlnLys *vs*.LysLys comparisons and Gln/Gln *vs*. Lys/Lys comparisons, but not in the other genetic models. We explored the source of heterogeneity for dominant model by cancer type, ethnicity, source of control, and found that esophageal cancer and hospital-based studies contributed to substantial heterogeneity (Table3). One reason may be that hospital-based studies had relatively small samples and were more prone to random error and false positive or negative results. Furthermore, it is very likely that the heterogeneity in esophageal studies and hospital-based studies are related since hospital-based studies predominate among the esophageal studies.

10.1371/journal.pone.0096301.t003

###### Heterogeneity test.

![](pone.0096301.t003){#pone-0096301-t003-3}

  Stratification       Gln Gln *vs*.LysLys   Gln Lys *vs*.LysLys   GlnGln+GlnLys *vs*.LysLys   GlnGln *vs*. GlnLys+LysLys
  ------------------- --------------------- --------------------- --------------------------- ----------------------------
  Digestive cancers        0.133, 20.9           0.064,27.6               0.011, 38.3                  0.385, 4.9
  Cancer type                                                                                 
  Esophageal cancer        0.033, 46.6           0.022, 49.3              0.004,58.2                   0.084,37.4
  Gastric cancer             0.930,0               0.554,0                  0.698,0                     0.864,0
  Colorectal cancer         0.310,13               0.470,0                0.328,12.2                   0.387,5.9
  Oral cancer               0.529, 0             0.095, 52.5              0.052,61.1                    0.795, 0
  Source of control                                                                           
  Hospital-based           0.043,39.6            0.051,38.2               0.006,51.6                   0.180,23.2
  Population-based           0.550,0             0.243,17.3               0.184,22.3                    0.715,0
  Ethnicity                                                                                   
  Asian                    0.287,14.2            0.174,24.2               0.057,38.0                   0.353,8.6
  European                 0.137, 26.3            0.074,334               0.029,41.2                   0.414,3.4

*Ph*: *P*-value of Q-test for heterogeneity identification; *I^2^* index: a quantitative measurement which indicates the proportion of total variation in study estimates that is due to between-study heterogeneity.

Publication Bias {#s3e}
----------------

Begg\'s rank correlation method and Egger\'s weighted regression method were used to assess publication bias. There was no evidence of publication bias in *XPD* Lys751Gln (Begg\'s test *P* = 0.284, Egger\'s test *P* = 0.324, t = 1.00, 95% CI = 0.41--1.21). We present funnel plot for ORs of Gln/Gln versus Lys/Lys ([Figure 5](#pone-0096301-g005){ref-type="fig"}).

![Begg\'s funnel plot for publication bias test (Homozygote comparison).\
Each point represents a separate study for the indicated association.](pone.0096301.g005){#pone-0096301-g005}

Discussion {#s4}
==========

XPD plays a crucial role in NER, which is significant in the elimination of certain DNA cross-links, ultraviolet (UV) photo-lesions, and bulky chemical adducts. The *XPD* protein possesses both single-strand DNA-dependant ATP ase and 5′-3′ DNA helicase activities, which is essential for NER pathway and transcription [@pone.0096301-Lunn1]. Genetic variation in *XPD* may contribute to impaired DNA repair capacity and increased cancer risk. The Lys to Gln change at position 751 of *XPD* results in complete changes about the charge configuration of the amino acid, which affects the interactions of *XPD* protein and its helicase activator [@pone.0096301-Pavanello1]. To date, a number of epidemiological studies have been conducted to evaluate the role of Lys751Gln polymorphism on several cancer risks, but the results remain controversial. As far as we know, several previous meta-analyses on *XPD* Lys751Gln polymorphism and cancers risk have been performed, such as gastric cancer, colorectal cancer, esophageal cancer, breast cancer and bladder cancer [@pone.0096301-Xue1]--[@pone.0096301-Wang1]. But to date, there is no meta-analysis on the association between digestive tract cancers risk and *XPD* Lys751Gln polymorphism. In order to derive a more precise estimation of relationship, we performed this meta-analysis of 37 studies, including 9027 cases and 16072 controls.

Through analyzing genotypes from the 37 eligible studies, we found the Gln/Gln genotype carries might be at potential risk to digestive tract cancers. The Lys to Gln variation on position 751 of *XPD* resulted in complete changes about the electronic configuration of the amino acid, which affected the interactions of *XPD* protein and its helicase activator [@pone.0096301-Coin1]. Digestive tract cancers represent a homogenous group of malignancies in some ways. Different primary sites of digestive tract cancers have some shared risk factors. For example, except for smoking and alcohol consumption, eating rough, spicy, hot and non-digestible food is likely to damage the digestive tract tissue. In addition, *H.Pylori* infection is a major cause of gastric cancer, while nitrites derived from red meat and processed meat is a key risk factor for esophageal cancer and colorectal cancer. Such risk factors and their tissue specificity raise the possibility that the *XPD* polymorphism may be associated with digestive tract cancers risk. The functional *XPD* Lys751Gln polymorphism resulting in decreased activity of *XPD* protein may increase risk of digestive tract cancers on the basis of damage tissue.

In stratified analysis by cancer type, we found that all genetic models did not appear to have an effect on the risks of esophageal, gastric, colorectal and oral cancers. This was different from Ling Yuan\'s and Wu XB\'s studies [@pone.0096301-Yuan3], [@pone.0096301-Wu1]. However Bo Chen et al. [@pone.0096301-Chen1] detected that Gln/Gln genotype carriers might have an increased risk of gastric cancer in the Helico-bacter pylori (H.pylori)-positive population, but not in the Helico-bacter pylori (H. pylori)-negative population. One possible explanation is that the modulation of digestive tract cancers risk may depend not only on a single gene/single nucleotide polymorphism, but also on a joint effect of multiple polymorphisms within different genes or pathways, or on close interaction between polymorphisms and environmental factor. The other is that Helicobacter pylori infection is one of the clear etiologies of gastric cancer and maybe there is some relationship between helicobacter pylori and the polymorphic loci. In the subgroup of ethnicity, we found significant association between *XPD* Gln/Gln polymorphism and increased risks of digestive tract cancers in Asians but not in European. We think ethnic differences and diverse live environment may partly explain the phenomenon. Furthermore, we believed differences in diet, such as food structure and cooking way, were the main cause of this result. In addition, it was also likely that the observed ethnic differences may be due to chance because studies with small sample size may have insufficient statistical power to detect a slight effect or may have generated a fluctuated risk estimate [@pone.0096301-Wacholder1].

In summary, this meta-analysis indicated that *XPD* Lys751Gln polymorphism, individuals carrying the variant homozygote Gln/Gln may increase the susceptibility of digestive tract cancers. And, significant associations were detected among Asians population. It should be noted explicitly: first, the effective sample size is much smaller for the Gln/Gln vs. Lys/Lys analyses than the other genetic models and therefore it is more prone to random error and false positive results; second, the results for GlnGln vs. GlyLys+LysLys, while not statistically significant (OR 1.09, 95% CI = 0.99--1.20, *P* = 0.072, *P* ~heterogeneity~ = 0.385), strengthen our conclusion about which genetic model is most appropriate. Large-scale case-control and population-based association studies are warranted to validate the risk identified in the current meta-analysis and investigate the potential gene-gene and gene-environment interactions on digestive tract cancers risk.
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